ANI Pharmaceuticals (ANIP) SVP reports tax-related share withholding on Form 4

Rhea-AI Filing Summary

ANI Pharmaceuticals SVP Chad Gassert reported a tax-related share withholding on company stock. On February 11, 2026, 4,269 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to the vesting of 11,578 performance stock units previously granted.

After this tax-withholding disposition, Gassert directly beneficially owned 69,346 shares of common stock. He also indirectly beneficially owned an additional 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gassert Chad

Role SVP - CORP. DEV. & STRATEGY

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,269	$76.25	$326K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 69,346 shares (Direct); Common Stock — 158,490 shares (Indirect, Held by Chali Properties LLC)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gassert Chad

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - CORP. DEV. & STRATEGY

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		F(1)		4,269	D	$76.25	69,346	D
Common Stock								158,490	I	Held by Chali Properties LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 11,578 performance stock units, the grant of which was previously reported on April 6, 2023.

2. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Remarks:

	/s/ Chad Gassert, by attorney-in-fact Meredith W. Cook	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ANI Pharmaceuticals (ANIP) insider Chad Gassert report on this Form 4?

Chad Gassert reported a tax-withholding disposition of 4,269 ANI Pharmaceuticals common shares at $76.25 per share. The shares were withheld to cover taxes from vesting of previously granted performance stock units, rather than an open-market sale.

How many ANI Pharmaceuticals (ANIP) shares does Chad Gassert own after the reported transaction?

After the transaction, Chad Gassert directly owned 69,346 ANI Pharmaceuticals common shares. He also indirectly beneficially owned 158,490 additional shares held by Chali Properties LLC, where he retains voting and dispositive power, according to the filing footnotes.

Was the ANI Pharmaceuticals (ANIP) Form 4 transaction an open-market sale?

No, the Form 4 describes a tax-withholding disposition, coded “F,” not an open-market sale. Shares were withheld by the issuer to satisfy tax obligations related to vesting of 11,578 performance stock units granted on April 6, 2023.

What role does Chali Properties LLC play in Chad Gassert’s ANI Pharmaceuticals (ANIP) holdings?

Chali Properties LLC holds 158,490 ANI Pharmaceuticals common shares reported as indirect ownership for Chad Gassert. The filing states he has voting and dispositive power over these shares, making them part of his beneficial ownership profile.

What triggered the tax withholding reported by ANI Pharmaceuticals (ANIP) SVP Chad Gassert?

The tax withholding was triggered by the vesting of 11,578 performance stock units previously granted to Chad Gassert. To cover associated tax obligations, 4,269 shares of common stock were withheld, an event exempt under Rule 16(b)-3 according to the disclosure.